PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
178.96%
R&D change of 178.96% versus flat Healthcare spending. Walter Schloss would verify adequacy.
203.49%
G&A change of 203.49% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
-29.56%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
185.87%
Operating expenses change of 185.87% versus flat Healthcare costs. Walter Schloss would verify control.
185.87%
Total costs change of 185.87% versus flat Healthcare costs. Walter Schloss would verify control.
-0.66%
Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-29.56%
D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.
-185.91%
EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-185.87%
Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
15.24%
Other expenses change of 15.24% versus flat Healthcare. Walter Schloss would verify control.
-92.79%
Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-92.79%
Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-3998.91%
EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
-3998.91%
Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
-95.29%
Share count reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.
-95.29%
Diluted share reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.